PE20250676A1 - Inhibidores de pi3k-alfa y metodos para su produccion y uso - Google Patents
Inhibidores de pi3k-alfa y metodos para su produccion y usoInfo
- Publication number
- PE20250676A1 PE20250676A1 PE2024001004A PE2024001004A PE20250676A1 PE 20250676 A1 PE20250676 A1 PE 20250676A1 PE 2024001004 A PE2024001004 A PE 2024001004A PE 2024001004 A PE2024001004 A PE 2024001004A PE 20250676 A1 PE20250676 A1 PE 20250676A1
- Authority
- PE
- Peru
- Prior art keywords
- pi3k
- compound
- acid
- alpha
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263474P | 2021-11-03 | 2021-11-03 | |
| CN2021128533 | 2021-11-03 | ||
| PCT/US2022/079221 WO2023081757A1 (en) | 2021-11-03 | 2022-11-03 | Pi3k-alpha inhibitors and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250676A1 true PE20250676A1 (es) | 2025-03-04 |
Family
ID=86242193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001004A PE20250676A1 (es) | 2021-11-03 | 2022-11-03 | Inhibidores de pi3k-alfa y metodos para su produccion y uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260125374A1 (enExample) |
| EP (1) | EP4426314A4 (enExample) |
| JP (1) | JP2024540303A (enExample) |
| KR (1) | KR20240112283A (enExample) |
| CN (1) | CN118401245A (enExample) |
| AU (1) | AU2022381187A1 (enExample) |
| CA (1) | CA3236861A1 (enExample) |
| CL (1) | CL2024001364A1 (enExample) |
| IL (1) | IL312466A (enExample) |
| MX (1) | MX2024005429A (enExample) |
| PE (1) | PE20250676A1 (enExample) |
| TW (1) | TW202334136A (enExample) |
| WO (1) | WO2023081757A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297625B2 (en) | 2020-04-29 | 2026-05-01 | Relay Therapeutics Inc | PI3K-alpha inhibitors and methods of using them |
| WO2024055992A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京再明医药有限公司 | 三环化合物及其应用 |
| WO2024097721A1 (en) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| KR20260005985A (ko) | 2023-05-05 | 2026-01-12 | 일라이 릴리 앤드 캄파니 | Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| MA38884A1 (fr) * | 2013-09-05 | 2017-06-30 | Hoffmann La Roche | Composé de triazolopyridine, compositions et procédés d'utilisation associés |
| WO2017000277A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| JP7426398B2 (ja) * | 2019-02-26 | 2024-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体 |
| IL297625B2 (en) * | 2020-04-29 | 2026-05-01 | Relay Therapeutics Inc | PI3K-alpha inhibitors and methods of using them |
-
2022
- 2022-11-02 TW TW111141786A patent/TW202334136A/zh unknown
- 2022-11-03 CA CA3236861A patent/CA3236861A1/en active Pending
- 2022-11-03 CN CN202280082873.4A patent/CN118401245A/zh active Pending
- 2022-11-03 WO PCT/US2022/079221 patent/WO2023081757A1/en not_active Ceased
- 2022-11-03 US US18/706,511 patent/US20260125374A1/en active Pending
- 2022-11-03 IL IL312466A patent/IL312466A/en unknown
- 2022-11-03 PE PE2024001004A patent/PE20250676A1/es unknown
- 2022-11-03 JP JP2024526614A patent/JP2024540303A/ja active Pending
- 2022-11-03 MX MX2024005429A patent/MX2024005429A/es unknown
- 2022-11-03 AU AU2022381187A patent/AU2022381187A1/en active Pending
- 2022-11-03 KR KR1020247018494A patent/KR20240112283A/ko active Pending
- 2022-11-03 EP EP22891040.2A patent/EP4426314A4/en active Pending
-
2024
- 2024-05-03 CL CL2024001364A patent/CL2024001364A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022381187A1 (en) | 2024-05-16 |
| EP4426314A1 (en) | 2024-09-11 |
| WO2023081757A1 (en) | 2023-05-11 |
| CA3236861A1 (en) | 2023-05-11 |
| EP4426314A4 (en) | 2025-10-01 |
| MX2024005429A (es) | 2024-05-21 |
| CN118401245A (zh) | 2024-07-26 |
| KR20240112283A (ko) | 2024-07-18 |
| JP2024540303A (ja) | 2024-10-31 |
| TW202334136A (zh) | 2023-09-01 |
| US20260125374A1 (en) | 2026-05-07 |
| CL2024001364A1 (es) | 2024-10-25 |
| IL312466A (en) | 2024-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010795A (es) | Hidrato cristalino de un compuesto inhibidor de jak. | |
| PE20231438A1 (es) | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| CO2024013702A2 (es) | Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3 | |
| CO2025008513A2 (es) | Derivados de n-fenil-pirazolo[1,5-a] piridina-3-carboxamida como inhibidores de la c-kit quinasa de tipo salvaje para el tratamiento de la urticaria | |
| DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| DOP2024000146A (es) | Inhibidores de parp7 | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| MX2025011458A (es) | Inhibidor de cyp11a1 y uso del mismo | |
| AR126215A1 (es) | Proceso novedoso | |
| DOP2025000090A (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| CO2025003090A2 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| AR126196A1 (es) | Proceso para preparar inhibidores de egfr | |
| MX2024009581A (es) | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1. | |
| AR133800A1 (es) | Compuestos de oxoisoindolinil piperidina-2,6-diona sustituida | |
| JOP20240183A1 (ar) | مثبطات بروتين رابط لإموباميل واستخداماتها | |
| AR129212A1 (es) | Compuestos piridona como inhibidores de trpa1 | |
| CL2023000648A1 (es) | Métodos para tratar enfermedades o afecciones mediadas por pde iv | |
| MX2022015532A (es) | Inhibidores selectivos de hdac6 y usos de los mismos. | |
| AR128498A1 (es) | Procesos novedosos | |
| ZA202310682B (en) | Nicotinamide ripk1 inhibitors |